Peabody O'Brien and Myers

2 downloads 123 Views 2MB Size Report
Karen Peabody O'Brien, Ph.D. Advancing Green Chemistry. Catalyzing Green Chemistry. Innovation though Key. Collaborations. Pete Myers, Ph.D.
Catalyzing Green Chemistry Innovation though Key Collaborations

Karen Peabody O’Brien, Ph.D. Advancing Green Chemistry Pete Myers, Ph.D. Environmental Health Sciences

What is Advancing Green Chemistry? A catalyst Identifying strategic leverage points to move the field forward faster Identifying critical needs and building capacity • Cross-pollination: Green chemistry and environmental health sciences • Science Communication

Cross-Pollinating EHS and GC Helping green chemists understand 21st century toxicology Building personal connections across the disciplines Inspiring new research agendas in EHS and GC Developing tools that green chemists can use Collaborations already underway

Who is engaged? Paul Anastas, US EPA John Warner, Warner Babcock Inst Amy Cannon, Beyond Benign Terry Collins, Carnegie Mellon CJ Li, McGill Buzz Cue, ACS GCI Wim Thielemans, Nottingham Adelina Voutchkova, Yale Evan Beach, Yale David Constable, GSK Klaus Kummerer, Germany James Wright, Australia

Linda Birnbaum, US NIEHS Jerry Heindel US NIEHS Thad Schug, US NIEHS Kris Thayer NIEHS Lynn Goldman, George Washington Bruce Blumberg UC Irvine Tom Zoeller, U. Massachusetts Fred vom Saal, Missouri Ruben Abagyan, UCSD Andrea Gore, U. Texas David Crews U. Texas Joe Thornton, U. Oregon Laura Vandenberg, Tufts Thea Edwards, Louisiana Tech Sarah Vogel, Columbia

Erice

Designing endocrine disruption out of the next generation of materials • A design protocol for green chemists • Principles behind the science of endocrine disruption

Designing a Testing Protocol • Collaboration of experts in biology, toxicology, and chemistry • Provide chemists with a process to eliminate potential harmful chemicals early in development (redirect resources). • Not regulatory, but will give chemists confidence that the molecules they are developing are safe for the environment and human health

Setting the course •Science advisory board: Jerry Heindel, National Institute of Environmental Health Sciences Fred Vom Saal, University of Missouri Peter Defur, Virginia Commonwealth University Andrea Gore, University of Texas David Crews, University of Texas Bruce Blumberg, University of California at Irvine Kris Thayer, National Institute of Environmental Health Sciences Terry Collins, Carnegie Mellon University John Warner, Warner-Babcock Institute Tom Zoeller, University of Massachusetts, Amherst Lou Guillette, University of South Carolina

• Close integration with EPA and NIEHS programs • NAS: meeting 9/12

Cavallo

Endocrine Disrupting Chemicals EDCs interfere with the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body which are responsible for the maintenance or homeostasis, reproduction, development and or behavior

Atrazine Phthalates BPA

PBDE’s

Perchlorates

Organotins

Endocrine Disrupting Chemicals HERBICIDES 2,4,-D 2,4,5,-T Alachlor Amitrole Atrazine Linuron Metribuzin Nitrofen Trifluralin

INSECTICIDES Aldicarb beta-HCH Carbaryl Chlordane Chlordecone DBCP Dicofol Dieldrin DDT and metabolites Endosulfan Heptachlor / H-epoxide Lindane (gamma-HCH) Malathion Methomyl Methoxychlor Oxychlordane Parathion Synthetic pyrethroids Transnonachlor Toxaphene

Pesticides

Flame Retardants

Herbicides

Industrial byproducts

FUNGICIDES Benomyl Ethylene thiourea Fenarimol Hexachlorobenzene Mancozeb Maneb Metiram - complex Tri-butyl-tin Vinclozolin Zineb

Fungicides

Surface protectors

Solvents

Sunscreens

METALS

Testosterone synthesis inhibitor Thyroid hormone disruptor

INDUSTRIAL CHEMICALS Bisphenol - A Polycarbonates Butylhydroxyanisole (BHA) Cadmium Chloro- & Bromo-diphenyl Dioxins Furans Lead Manganese Methyl mercury Nonylphenol Octylphenol PBDEs PCBs Pentachlorophenol Penta- to Nonylphenols Perchlorate PFOA p-tert-Pentylphenol Phthalates Styrene

Plastics

Plasticizers

Cosmetics

Over 1,000 EDCs

Estrogen receptor agonist Androgen receptor antagonist

Testing Program Goals • Scientifically sound tests to determine endocrine activity • Logical step-by-step, easy to follow, save time and $$$ • Tiered approach: Start where needed • Variety of tests to choose from within each Tier • Assays with acceptable performance standards, proper positive and negative controls, validated, up-to-date • Start now: expand, adapt, and improve…

Tiered Testing Strategy Phase 1

Phase 2

Phase 3

Phase 4

Phase 5 Rat

Computational/ QSAR modeling

HTS in vitro biochemical or cell-based assays

Secondary whole cell specialized in vitro assays

In vivo fish/amphibian Screen

In vivo mammalian evaluation

Where We Stand • Writing a consensus statement establishing principles and guidelines for testing EDCs • Developing a detailed protocol for each phase of testing  Tests that cover a wide range of mechanisms, proper standards and validation  Growing database that can adapt to new tests and technologies • Establishing partnerships between EHS and Chemists to educate and disseminate the program

Science Communication Fellows Collaboration between AGC, EHS and Science Communication Network 10 Fellows each year Annual meeting; monthly calls

Science Communication Fellows

Thank you Kendeda Fund Johnson Family Fund John Merck Fund NIEHS

www.EnvironmentalHealthNews.org www.AdvancingGreenChemistry.org